uric acid has been researched along with Multiple Sclerosis in 66 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
Multiple Sclerosis: An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Recently we conducted a clinical trial to determine whether raising the serum UA levels through the oral administration of inosine is well tolerated and may benefit patients with multiple sclerosis." | 9.14 | Modulation of serum uric acid levels by inosine in patients with multiple sclerosis does not affect blood pressure. ( Hooper, DC; Koprowski, H; Markowitz, CE; Spitsin, S; Zimmerman, V, 2010) |
| "Several studies indicate that patients with multiple sclerosis (MS) have low serum levels of the endogenous antioxidant uric acid (UA), although it has not been established whether UA is primarily deficient or secondarily reduced due to its peroxynitrite scavenging activity." | 9.10 | Serum uric acid and multiple sclerosis. ( Arru, G; Fois, ML; Pugliatti, M; Rosati, G; Sanna, A; Sotgiu, A; Sotgiu, S, 2002) |
| "Serum uric acid (UA), a natural scavenger of peroxynitrite, has been found to be of lower levels in patients with multiple sclerosis (MS) in some recent preliminary studies." | 8.88 | Serum uric acid levels in patients with multiple sclerosis: a meta-analysis. ( Cen, L; Liu, B; Shen, Y; Tang, Y; Wei, J; Xiao, K, 2012) |
| "sk Keywords: neutrophil/lymphocyte ratio, uric acid, multiple sclerosis, inflammation, Expanded Disability Status Scale." | 8.02 | The relationship between neutrophil/lymphocyte ratio and uric acid levels in multiple sclerosis patients. ( Bolayir, A; Cigdem, B; Gokce, SF; Yilmaz, D, 2021) |
| "It has been reported that patients with multiple sclerosis (MS) exhibit lower serum uric acid levels; however, the association between uric acid concentrations and benign MS (BMS) has not been assessed." | 7.85 | Serum uric acid concentrations are directly associated with the presence of benign multiple sclerosis. ( Guerrero-Romero, F; Simental-Mendía, E; Simental-Mendía, LE, 2017) |
| "Previous studies have shown that serum uric acid (UA) modulates outcomes of neurological diseases, although little is known about cerebrospinal fluid (CSF) UA levels in neuromyelitis optica spectrum disorders (NMOSDs)." | 7.85 | Elevated cerebrospinal fluid uric acid during relapse of neuromyelitis optica spectrum disorders. ( Hu, X; Li, H; Li, R; Long, Y; Lu, Z; Peng, F; Qiu, W; Shu, Y; Wang, Y; Zhang, L, 2017) |
| "The lower levels of serum uric acid (UA) correlated with meningitis have been reported." | 7.83 | Serum uric acid levels in patients with infections of central nervous system. ( Li, M; Liu, J; Peng, FH; Wang, X; Xu, L; Yi, H; Zhong, XF, 2016) |
| "Uric acid (UA) is a strong natural scavenger of reactive oxygen and nitrogen species, with evidence of possible use in the treatment of animal models of multiple sclerosis (MS)." | 7.81 | Uric acid: a potential biomarker of multiple sclerosis and of its disability. ( Carotenuto, A; Lanzillo, R; Massarelli, M; Moccia, M; Morra, VB; Nardone, A; Palladino, R; Russo, C; Triassi, M; Vacca, G; Vacchiano, V, 2015) |
| "Uric acid (UA) has been suggested to be a marker of multiple sclerosis (MS) activity." | 7.79 | Long-term effects of whole body cryostimulation on uric acid concentration in plasma of secondary progressive multiple sclerosis patients. ( Miller, E; Morel, A; Saluk, J; Wachowicz, B, 2013) |
| "Uric acid (UA), a product of purine metabolism, is known to be reduced in patients with various neurological disorders including multiple sclerosis (MS)." | 7.78 | Reduced serum uric acid levels in neuromyelitis optica: serum uric acid levels are reduced during relapses in NMO. ( H Lee, K; Kim, BJ; Lee, S; Min, JH; Vincent, A; Waters, P; Y Shin, H, 2012) |
| " 388 individuals, including 97 patients with myasthenia gravis (MG), 135 patients with multiple sclerosis (MS) and 156 healthy controls, were assessed for serum levels of bilirubin and uric acid (UA), in order to determine the levels of these natural antioxidants in the serum." | 7.78 | Antioxidant status of bilirubin and uric acid in patients with myasthenia gravis. ( Feng, T; Fuhua, P; Jia, L; Lijia, G; Xueqiang, H; Xuhui, D; Ying, J; Yu, Y; Zhiyang, Z, 2012) |
| "To explore the correlations between serum uric acid (UA) levels and the clinical and cerebrospinal fluid (CSF) parameters of multiple sclerosis (MS)." | 7.78 | Correlations between serum uric acid level and disease activity, intrathecal inflammation reactivity in patients with multiple sclerosis. ( Chen, XW; Cui, LY; Liu, CY; Peng, B; Wang, JM; Xu, Y; Zhong, LZ, 2012) |
| "Multiple Sclerosis (MS) patients present a decrease of antioxidants and neuroprotective and immunoregulatory vitamins and an increase of total homocysteine (tHcy), cholesterol (CHL), HDL-cholesterol, and of cellular stress markers, variably associated with the different phases of the disease." | 7.76 | Blood lipids, homocysteine, stress factors, and vitamins in clinically stable multiple sclerosis patients. ( Battaglieri, F; Bono, A; Gueli, MC; Guglielmini, E; Massenti, MF; Ragonese, P; Salemi, G; Savettieri, G; Trentacosti, A; Vitale, F, 2010) |
| "Uric acid (UA) has been reported to be reduced in the serum of patients with multiple sclerosis (MS) and optic neuritis (ON)." | 7.76 | Serum uric acid levels and neuromyelitis optica. ( Dai, Y; Deng, X; Hu, X; Jiang, Y; Li, Q; Long, Y; Peng, F; Qiu, W; Wu, A; Zhong, X, 2010) |
| "In this study, the concentrations of uric acid, purine profile and creatinine in samples of cerebrospinal fluid and serum of multiple sclerosis (MS) patients were measured by HPLC and compared with corresponding values recorded in patients without MS (cerebrospinal fluid) and healthy subjects (serum)." | 7.75 | Increase of uric acid and purine compounds in biological fluids of multiple sclerosis patients. ( Amorini, AM; Belli, A; D'Urso, S; Di Pietro, V; Eikelenboom, J; Giovannoni, G; Keir, G; Lazzarino, G; Petzold, A; Polman, C; Tavazzi, B; Uitdehaag, B; Vagnozzi, R, 2009) |
| "The serum uric acid (UA) levels were measured in 112 patients with multiple sclerosis (MS) and 794 patients with different types of other neurological diseases (OND) or healthy control group." | 7.74 | Serum uric acid levels of patients with multiple sclerosis and other neurological diseases. ( Hu, X; Li, J; Pei, Z; Peng, F; Qiu, W; Xu, G; Zhang, B; Zhong, X, 2008) |
| "A number of studies found that patients with multiple sclerosis (MS) have low serum levels of uric acid." | 7.73 | Serum uric acid levels and leukocyte nitric oxide production in multiple sclerosis patients outside relapses. ( De Keyser, J; Heerings, M; Heersema, DJ; Mostert, JP; Ramsaransing, GS; Wilczak, N, 2005) |
| "Uric acid, an antioxidant, is reduced in multiple sclerosis (MS)." | 7.72 | Serum uric acid levels in optic neuritis. ( Cherryman, GR; Constantinescu, CS; Gottlob, I; Knapp, CM; McLean, R; Tan, JH, 2004) |
| "The levels of uric acid (UA), a natural peroxynitrite scavenger, were measured in sera from 240 patients with multiple sclerosis (MS) and 104 sex- and age-matched control patients with other neurological diseases (OND)." | 7.71 | Uric acid levels in sera from patients with multiple sclerosis. ( Andjelković, S; Dragutinović, G; Drulović, J; Dujmović, I; Lević, Z; Marinković, J; Mesaros, S; Miljković, D; Mostarica Stojković, M; Perić, V; Stojsavljević, N, 2001) |
| "Uric acid (UA) is a purine metabolite that selectively inhibits peroxynitrite-mediated reactions implicated in the pathogenesis of multiple sclerosis (MS) and other neurodegenerative diseases." | 7.71 | Therapeutic intervention in experimental allergic encephalomyelitis by administration of uric acid precursors. ( Hooper, DC; Kean, RB; Koprowski, H; Mikheeva, T; Scott, GS; Spitsin, SV, 2002) |
| "The levels of the antioxidants ascorbic acid, cysteine, reduced glutathione and alpha-tocopherol, of the free-radical marker uric acid and of the amino acids tyrosine and tryptophan were measured by means of high-pressure liquid chromatography in plaques, adjacent white matter and distant white matter from patients with multiple sclerosis, and in central nervous system tissue from patients without neurological diseases." | 7.68 | Measurement of low-molecular-weight antioxidants, uric acid, tyrosine and tryptophan in plaques and white matter from patients with multiple sclerosis. ( Kabiersch, A; Langemann, H; Newcombe, J, 1992) |
| "Neurodegenerative diseases, such as Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS), currently represent major unmet medical needs." | 6.82 | Inosine in Neurodegenerative Diseases: From the Bench to the Bedside. ( Basile, MS; Bramanti, P; Mazzon, E, 2022) |
| "Uric acid (UA) is an endogenous antioxidant." | 5.37 | Serum uric acid levels in multiple sclerosis patients inversely correlate with disability. ( Guerrero, AL; Gutiérrez, F; Iglesias, F; Laherrán, E; Martín-Polo, J; Martín-Serradilla, JI; Merino, S; Tejero, MA, 2011) |
| "Uric acid (UA) was shown to be a strong peroxynitrite scavenger." | 5.35 | Cerebrospinal fluid and serum uric acid levels in patients with multiple sclerosis. ( Drulovic, J; Dujmovic, I; Mostarica Stojkovic, M; Nikolić, A; Obrenovic, R; Pekmezovic, T; Spasic, M, 2009) |
| "Uric acid treatment also was found to diminish clinical signs of a disease resembling EAE in interferon-gamma receptor knockout mice." | 5.30 | Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. ( Champion, JM; Chaudhry, I; Dickson, GM; Hooper, DC; Kean, RB; Koprowski, H; Spitsin, S, 1998) |
| " Recently we conducted a clinical trial to determine whether raising the serum UA levels through the oral administration of inosine is well tolerated and may benefit patients with multiple sclerosis." | 5.14 | Modulation of serum uric acid levels by inosine in patients with multiple sclerosis does not affect blood pressure. ( Hooper, DC; Koprowski, H; Markowitz, CE; Spitsin, S; Zimmerman, V, 2010) |
| "Several studies indicate that patients with multiple sclerosis (MS) have low serum levels of the endogenous antioxidant uric acid (UA), although it has not been established whether UA is primarily deficient or secondarily reduced due to its peroxynitrite scavenging activity." | 5.10 | Serum uric acid and multiple sclerosis. ( Arru, G; Fois, ML; Pugliatti, M; Rosati, G; Sanna, A; Sotgiu, A; Sotgiu, S, 2002) |
| "Serum uric acid (UA), a natural scavenger of peroxynitrite, has been found to be of lower levels in patients with multiple sclerosis (MS) in some recent preliminary studies." | 4.88 | Serum uric acid levels in patients with multiple sclerosis: a meta-analysis. ( Cen, L; Liu, B; Shen, Y; Tang, Y; Wei, J; Xiao, K, 2012) |
| "sk Keywords: neutrophil/lymphocyte ratio, uric acid, multiple sclerosis, inflammation, Expanded Disability Status Scale." | 4.02 | The relationship between neutrophil/lymphocyte ratio and uric acid levels in multiple sclerosis patients. ( Bolayir, A; Cigdem, B; Gokce, SF; Yilmaz, D, 2021) |
| "Previous studies have shown that serum uric acid (UA) modulates outcomes of neurological diseases, although little is known about cerebrospinal fluid (CSF) UA levels in neuromyelitis optica spectrum disorders (NMOSDs)." | 3.85 | Elevated cerebrospinal fluid uric acid during relapse of neuromyelitis optica spectrum disorders. ( Hu, X; Li, H; Li, R; Long, Y; Lu, Z; Peng, F; Qiu, W; Shu, Y; Wang, Y; Zhang, L, 2017) |
| "It has been reported that patients with multiple sclerosis (MS) exhibit lower serum uric acid levels; however, the association between uric acid concentrations and benign MS (BMS) has not been assessed." | 3.85 | Serum uric acid concentrations are directly associated with the presence of benign multiple sclerosis. ( Guerrero-Romero, F; Simental-Mendía, E; Simental-Mendía, LE, 2017) |
| "The lower levels of serum uric acid (UA) correlated with meningitis have been reported." | 3.83 | Serum uric acid levels in patients with infections of central nervous system. ( Li, M; Liu, J; Peng, FH; Wang, X; Xu, L; Yi, H; Zhong, XF, 2016) |
| "This study investigated the epidemiological evidence for a protective role of high serum concentration of uric acid, for which we used gout as a proxy, in the aetiology of MS, PD or MND." | 3.81 | Clinical associations between gout and multiple sclerosis, Parkinson's disease and motor neuron disease: record-linkage studies. ( Goldacre, MJ; Pakpoor, J; Ramagopalan, SV; Seminog, OO, 2015) |
| "Uric acid (UA) is a strong natural scavenger of reactive oxygen and nitrogen species, with evidence of possible use in the treatment of animal models of multiple sclerosis (MS)." | 3.81 | Uric acid: a potential biomarker of multiple sclerosis and of its disability. ( Carotenuto, A; Lanzillo, R; Massarelli, M; Moccia, M; Morra, VB; Nardone, A; Palladino, R; Russo, C; Triassi, M; Vacca, G; Vacchiano, V, 2015) |
| "Uric acid (UA) has been suggested to be a marker of multiple sclerosis (MS) activity." | 3.79 | Long-term effects of whole body cryostimulation on uric acid concentration in plasma of secondary progressive multiple sclerosis patients. ( Miller, E; Morel, A; Saluk, J; Wachowicz, B, 2013) |
| " 388 individuals, including 97 patients with myasthenia gravis (MG), 135 patients with multiple sclerosis (MS) and 156 healthy controls, were assessed for serum levels of bilirubin and uric acid (UA), in order to determine the levels of these natural antioxidants in the serum." | 3.78 | Antioxidant status of bilirubin and uric acid in patients with myasthenia gravis. ( Feng, T; Fuhua, P; Jia, L; Lijia, G; Xueqiang, H; Xuhui, D; Ying, J; Yu, Y; Zhiyang, Z, 2012) |
| "Uric acid (UA), a product of purine metabolism, is known to be reduced in patients with various neurological disorders including multiple sclerosis (MS)." | 3.78 | Reduced serum uric acid levels in neuromyelitis optica: serum uric acid levels are reduced during relapses in NMO. ( H Lee, K; Kim, BJ; Lee, S; Min, JH; Vincent, A; Waters, P; Y Shin, H, 2012) |
| "To explore the correlations between serum uric acid (UA) levels and the clinical and cerebrospinal fluid (CSF) parameters of multiple sclerosis (MS)." | 3.78 | Correlations between serum uric acid level and disease activity, intrathecal inflammation reactivity in patients with multiple sclerosis. ( Chen, XW; Cui, LY; Liu, CY; Peng, B; Wang, JM; Xu, Y; Zhong, LZ, 2012) |
| "Multiple Sclerosis (MS) patients present a decrease of antioxidants and neuroprotective and immunoregulatory vitamins and an increase of total homocysteine (tHcy), cholesterol (CHL), HDL-cholesterol, and of cellular stress markers, variably associated with the different phases of the disease." | 3.76 | Blood lipids, homocysteine, stress factors, and vitamins in clinically stable multiple sclerosis patients. ( Battaglieri, F; Bono, A; Gueli, MC; Guglielmini, E; Massenti, MF; Ragonese, P; Salemi, G; Savettieri, G; Trentacosti, A; Vitale, F, 2010) |
| "Uric acid (UA) has been reported to be reduced in the serum of patients with multiple sclerosis (MS) and optic neuritis (ON)." | 3.76 | Serum uric acid levels and neuromyelitis optica. ( Dai, Y; Deng, X; Hu, X; Jiang, Y; Li, Q; Long, Y; Peng, F; Qiu, W; Wu, A; Zhong, X, 2010) |
| "In this study, the concentrations of uric acid, purine profile and creatinine in samples of cerebrospinal fluid and serum of multiple sclerosis (MS) patients were measured by HPLC and compared with corresponding values recorded in patients without MS (cerebrospinal fluid) and healthy subjects (serum)." | 3.75 | Increase of uric acid and purine compounds in biological fluids of multiple sclerosis patients. ( Amorini, AM; Belli, A; D'Urso, S; Di Pietro, V; Eikelenboom, J; Giovannoni, G; Keir, G; Lazzarino, G; Petzold, A; Polman, C; Tavazzi, B; Uitdehaag, B; Vagnozzi, R, 2009) |
| "The serum uric acid (UA) levels were measured in 112 patients with multiple sclerosis (MS) and 794 patients with different types of other neurological diseases (OND) or healthy control group." | 3.74 | Serum uric acid levels of patients with multiple sclerosis and other neurological diseases. ( Hu, X; Li, J; Pei, Z; Peng, F; Qiu, W; Xu, G; Zhang, B; Zhong, X, 2008) |
| "A number of studies found that patients with multiple sclerosis (MS) have low serum levels of uric acid." | 3.73 | Serum uric acid levels and leukocyte nitric oxide production in multiple sclerosis patients outside relapses. ( De Keyser, J; Heerings, M; Heersema, DJ; Mostert, JP; Ramsaransing, GS; Wilczak, N, 2005) |
| "Uric acid, an antioxidant, is reduced in multiple sclerosis (MS)." | 3.72 | Serum uric acid levels in optic neuritis. ( Cherryman, GR; Constantinescu, CS; Gottlob, I; Knapp, CM; McLean, R; Tan, JH, 2004) |
| "Uric acid (UA) is a purine metabolite that selectively inhibits peroxynitrite-mediated reactions implicated in the pathogenesis of multiple sclerosis (MS) and other neurodegenerative diseases." | 3.71 | Therapeutic intervention in experimental allergic encephalomyelitis by administration of uric acid precursors. ( Hooper, DC; Kean, RB; Koprowski, H; Mikheeva, T; Scott, GS; Spitsin, SV, 2002) |
| "The levels of uric acid (UA), a natural peroxynitrite scavenger, were measured in sera from 240 patients with multiple sclerosis (MS) and 104 sex- and age-matched control patients with other neurological diseases (OND)." | 3.71 | Uric acid levels in sera from patients with multiple sclerosis. ( Andjelković, S; Dragutinović, G; Drulović, J; Dujmović, I; Lević, Z; Marinković, J; Mesaros, S; Miljković, D; Mostarica Stojković, M; Perić, V; Stojsavljević, N, 2001) |
| "The levels of the antioxidants ascorbic acid, cysteine, reduced glutathione and alpha-tocopherol, of the free-radical marker uric acid and of the amino acids tyrosine and tryptophan were measured by means of high-pressure liquid chromatography in plaques, adjacent white matter and distant white matter from patients with multiple sclerosis, and in central nervous system tissue from patients without neurological diseases." | 3.68 | Measurement of low-molecular-weight antioxidants, uric acid, tyrosine and tryptophan in plaques and white matter from patients with multiple sclerosis. ( Kabiersch, A; Langemann, H; Newcombe, J, 1992) |
| "Neurodegenerative diseases, such as Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS), currently represent major unmet medical needs." | 2.82 | Inosine in Neurodegenerative Diseases: From the Bench to the Bedside. ( Basile, MS; Bramanti, P; Mazzon, E, 2022) |
| "The medical understanding of autism has changed since it was first defined by Kanner." | 2.46 | The review of most frequently occurring medical disorders related to aetiology of autism and the methods of treatment. ( Cubala-Kucharska, M, 2010) |
| "Inflammasome-driven inflammation is postulated to play a role in multiple sclerosis (MS), but there is no direct evidence that the nod-like receptor protein 3 (NLRP3) inflammasome is involved in MS pathogenesis." | 1.48 | Monosodium Urate Crystals Activate the Inflammasome in Primary Progressive Multiple Sclerosis. ( Caputo, D; Clerici, M; La Rosa, F; Marventano, I; Mendozzi, L; Piancone, F; Rovaris, M; Santangelo, MA; Saresella, M, 2018) |
| "Uric acid (UA) is an endogenous antioxidant." | 1.37 | Serum uric acid levels in multiple sclerosis patients inversely correlate with disability. ( Guerrero, AL; Gutiérrez, F; Iglesias, F; Laherrán, E; Martín-Polo, J; Martín-Serradilla, JI; Merino, S; Tejero, MA, 2011) |
| "Uric acid (UA) was shown to be a strong peroxynitrite scavenger." | 1.35 | Cerebrospinal fluid and serum uric acid levels in patients with multiple sclerosis. ( Drulovic, J; Dujmovic, I; Mostarica Stojkovic, M; Nikolić, A; Obrenovic, R; Pekmezovic, T; Spasic, M, 2009) |
| "Uric acid (UA) is a natural scavenger of ONOO(-) that is present at high levels in the sera of humans and other higher order primates relative to most lower mammals." | 1.31 | Protection of myelin basic protein immunized mice from free-radical mediated inflammatory cell invasion of the central nervous system by the natural peroxynitrite scavenger uric acid. ( Hooper, DC; Kean, RB; Mikheeva, T; Scott, GS; Spitsin, SV, 2000) |
| "Uric acid treatment also was found to diminish clinical signs of a disease resembling EAE in interferon-gamma receptor knockout mice." | 1.30 | Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. ( Champion, JM; Chaudhry, I; Dickson, GM; Hooper, DC; Kean, RB; Koprowski, H; Spitsin, S, 1998) |
| "In multiple sclerosis, myelopathy, stroke, epilepsy and viral meningitis glutamate, hypoxanthine, xanthine, and uric acid are increased 2-3-fold compared to controls." | 1.30 | Cerebrospinal fluid hypoxanthine, xanthine and uric acid levels may reflect glutamate-mediated excitotoxicity in different neurological diseases. ( Kempski, OS; Lowitzsch, K; Stover, JF, 1997) |
| "Uric acid was successfully used to treat experimental allergic encephalomyelitis, the mouse model of multiple sclerosis (M." | 1.30 | [Uric acid as a scavenger in oxidative stress]. ( Staub, M, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (4.55) | 18.7374 |
| 1990's | 6 (9.09) | 18.2507 |
| 2000's | 29 (43.94) | 29.6817 |
| 2010's | 25 (37.88) | 24.3611 |
| 2020's | 3 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Basile, MS | 1 |
| Bramanti, P | 1 |
| Mazzon, E | 1 |
| Harroud, A | 1 |
| Richards, JB | 1 |
| Baranzini, SE | 1 |
| Bolayir, A | 1 |
| Cigdem, B | 1 |
| Gokce, SF | 1 |
| Yilmaz, D | 1 |
| Simental-Mendía, E | 1 |
| Simental-Mendía, LE | 1 |
| Guerrero-Romero, F | 1 |
| You, Z | 1 |
| Timilshina, M | 1 |
| Jeong, BS | 1 |
| Chang, JH | 1 |
| Piancone, F | 1 |
| Saresella, M | 1 |
| Marventano, I | 1 |
| La Rosa, F | 1 |
| Santangelo, MA | 1 |
| Caputo, D | 1 |
| Mendozzi, L | 1 |
| Rovaris, M | 1 |
| Clerici, M | 1 |
| Flauzino, T | 2 |
| Simão, ANC | 1 |
| de Carvalho Jennings Pereira, WL | 1 |
| Alfieri, DF | 2 |
| Oliveira, SR | 2 |
| Kallaur, AP | 2 |
| Lozovoy, MAB | 1 |
| Kaimen-Maciel, DR | 2 |
| Maes, M | 2 |
| Reiche, EMV | 1 |
| Moynihan, J | 2 |
| Davis, E | 1 |
| Moore, H | 2 |
| Miller, E | 1 |
| Saluk, J | 1 |
| Morel, A | 1 |
| Wachowicz, B | 1 |
| Moccia, M | 1 |
| Lanzillo, R | 1 |
| Palladino, R | 1 |
| Russo, C | 1 |
| Carotenuto, A | 1 |
| Massarelli, M | 1 |
| Vacca, G | 1 |
| Vacchiano, V | 1 |
| Nardone, A | 1 |
| Triassi, M | 1 |
| Morra, VB | 1 |
| Pakpoor, J | 1 |
| Seminog, OO | 1 |
| Ramagopalan, SV | 1 |
| Goldacre, MJ | 1 |
| Liu, J | 1 |
| Li, M | 1 |
| Wang, X | 1 |
| Yi, H | 1 |
| Xu, L | 1 |
| Zhong, XF | 1 |
| Peng, FH | 1 |
| Wang, L | 1 |
| Hu, W | 1 |
| Wang, J | 1 |
| Qian, W | 1 |
| Xiao, H | 1 |
| Karampoor, S | 1 |
| Zahednasab, H | 1 |
| Ramagopalan, S | 1 |
| Mehrpour, M | 1 |
| Keyvani, H | 1 |
| Shu, Y | 1 |
| Li, H | 1 |
| Zhang, L | 1 |
| Wang, Y | 1 |
| Long, Y | 2 |
| Li, R | 1 |
| Qiu, W | 3 |
| Lu, Z | 1 |
| Hu, X | 3 |
| Peng, F | 3 |
| Lopes, J | 1 |
| Colado Simão, AN | 1 |
| Reiche, EM | 1 |
| de Almeida, ERD | 1 |
| Morimoto, HK | 1 |
| de Carvalho Jennings de Pereira, WL | 1 |
| de Meleck Proença, C | 1 |
| Gomes, AM | 1 |
| Amorini, AM | 1 |
| Petzold, A | 1 |
| Tavazzi, B | 1 |
| Eikelenboom, J | 1 |
| Keir, G | 1 |
| Belli, A | 1 |
| Giovannoni, G | 1 |
| Di Pietro, V | 1 |
| Polman, C | 1 |
| D'Urso, S | 1 |
| Vagnozzi, R | 1 |
| Uitdehaag, B | 1 |
| Lazzarino, G | 1 |
| Massa, J | 1 |
| O'Reilly, E | 1 |
| Munger, KL | 1 |
| Delorenze, GN | 1 |
| Ascherio, A | 1 |
| Dujmovic, I | 2 |
| Pekmezovic, T | 1 |
| Obrenovic, R | 1 |
| Nikolić, A | 1 |
| Spasic, M | 1 |
| Mostarica Stojkovic, M | 2 |
| Drulovic, J | 2 |
| Whitmarsh, TE | 1 |
| Spitsin, S | 4 |
| Markowitz, CE | 1 |
| Zimmerman, V | 1 |
| Koprowski, H | 8 |
| Hooper, DC | 10 |
| Zhong, X | 2 |
| Deng, X | 1 |
| Wu, A | 1 |
| Li, Q | 1 |
| Jiang, Y | 1 |
| Dai, Y | 1 |
| Salemi, G | 1 |
| Gueli, MC | 1 |
| Vitale, F | 1 |
| Battaglieri, F | 1 |
| Guglielmini, E | 1 |
| Ragonese, P | 1 |
| Trentacosti, A | 1 |
| Massenti, MF | 1 |
| Savettieri, G | 1 |
| Bono, A | 1 |
| Cubala-Kucharska, M | 1 |
| Guerrero, AL | 2 |
| Gutiérrez, F | 2 |
| Iglesias, F | 2 |
| Martín-Polo, J | 2 |
| Merino, S | 1 |
| Martín-Serradilla, JI | 1 |
| Laherrán, E | 2 |
| Tejero, MA | 2 |
| Hadžović-Džuvo, A | 1 |
| Lepara, O | 1 |
| Valjevac, A | 1 |
| Avdagić, N | 1 |
| Hasić, S | 1 |
| Kiseljaković, E | 1 |
| Ibragić, S | 1 |
| Alajbegović, A | 1 |
| Fuhua, P | 1 |
| Xuhui, D | 1 |
| Zhiyang, Z | 1 |
| Ying, J | 1 |
| Yu, Y | 1 |
| Feng, T | 1 |
| Jia, L | 1 |
| Lijia, G | 1 |
| Xueqiang, H | 1 |
| Min, JH | 1 |
| Waters, P | 1 |
| Vincent, A | 1 |
| Lee, S | 1 |
| Y Shin, H | 1 |
| H Lee, K | 1 |
| Kim, BJ | 1 |
| Liu, B | 1 |
| Shen, Y | 1 |
| Xiao, K | 1 |
| Tang, Y | 1 |
| Cen, L | 1 |
| Wei, J | 1 |
| Liu, CY | 1 |
| Xu, Y | 1 |
| Cui, LY | 1 |
| Peng, B | 1 |
| Zhong, LZ | 1 |
| Chen, XW | 1 |
| Wang, JM | 1 |
| Zoccolella, S | 1 |
| Tortorella, C | 1 |
| Iaffaldano, P | 1 |
| Direnzo, V | 1 |
| D'Onghia, M | 1 |
| Luciannatelli, E | 1 |
| Paolicelli, D | 1 |
| Livrea, P | 1 |
| Trojano, M | 1 |
| Toncev, G | 1 |
| Milicic, B | 1 |
| Toncev, S | 1 |
| Samardzic, G | 1 |
| Scott, GS | 4 |
| Spitsin, SV | 4 |
| Kean, RB | 4 |
| Mikheeva, T | 4 |
| Sotgiu, S | 1 |
| Pugliatti, M | 1 |
| Sanna, A | 1 |
| Sotgiu, A | 1 |
| Fois, ML | 1 |
| Arru, G | 1 |
| Rosati, G | 1 |
| Mousavizadeh, K | 1 |
| Dehpour, AR | 1 |
| Minagar, A | 1 |
| Ghafourifar, P | 1 |
| Miller, A | 2 |
| Glass-Marmor, L | 1 |
| Abraham, M | 1 |
| Grossman, I | 1 |
| Shapiro, S | 1 |
| Galboiz, Y | 2 |
| Knapp, CM | 1 |
| Constantinescu, CS | 1 |
| Tan, JH | 1 |
| McLean, R | 1 |
| Cherryman, GR | 1 |
| Gottlob, I | 1 |
| Kanabrocki, EL | 2 |
| Ryan, MD | 2 |
| Hermida, RC | 2 |
| Ayala, DE | 1 |
| Murray, D | 1 |
| Bremner, WF | 2 |
| Third, JL | 2 |
| Johnson, MC | 1 |
| Foley, S | 1 |
| Van Cauteren, J | 1 |
| Shah, F | 1 |
| Shirazi, P | 2 |
| Nemchausky, BA | 2 |
| Mattle, HP | 1 |
| Lienert, C | 1 |
| Greeve, I | 1 |
| Becker, BF | 2 |
| Kastenbauer, S | 2 |
| Ködel, U | 1 |
| Kiesl, D | 1 |
| Pfister, HW | 1 |
| Kieseier, BC | 1 |
| Mostert, JP | 1 |
| Ramsaransing, GS | 2 |
| Heersema, DJ | 2 |
| Heerings, M | 1 |
| Wilczak, N | 1 |
| De Keyser, J | 3 |
| Rentzos, M | 1 |
| Nikolaou, C | 1 |
| Anagnostouli, M | 1 |
| Rombos, A | 1 |
| Tsakanikas, K | 1 |
| Economou, M | 1 |
| Dimitrakopoulos, A | 1 |
| Karouli, M | 1 |
| Vassilopoulos, D | 1 |
| Koch, M | 1 |
| Zhang, B | 1 |
| Li, J | 1 |
| Xu, G | 1 |
| Pei, Z | 1 |
| Rodríguez-Gallego, M | 1 |
| Alcázar, C | 1 |
| Zamani, A | 1 |
| Rezaei, A | 1 |
| Khaeir, F | 1 |
| Kuracka, L | 1 |
| Kalnovicová, T | 1 |
| Líska, B | 1 |
| Turcáni, P | 1 |
| Bagasra, O | 1 |
| Marini, JC | 1 |
| Zborek, A | 2 |
| Ohnishi, ST | 1 |
| Kean, R | 1 |
| Champion, JM | 2 |
| Sarker, AB | 1 |
| Bobroski, L | 1 |
| Farber, JL | 1 |
| Akaike, T | 1 |
| Maeda, H | 1 |
| Dickson, GM | 1 |
| Chaudhry, I | 1 |
| Stover, JF | 1 |
| Lowitzsch, K | 1 |
| Kempski, OS | 1 |
| Staub, M | 1 |
| Scheving, LE | 1 |
| McCormick, JB | 1 |
| Hoppensteadt, DA | 1 |
| Fareed, J | 1 |
| Olwin, JH | 1 |
| Stojsavljević, N | 1 |
| Mesaros, S | 1 |
| Andjelković, S | 1 |
| Miljković, D | 1 |
| Perić, V | 1 |
| Dragutinović, G | 1 |
| Marinković, J | 1 |
| Lević, Z | 1 |
| Langemann, H | 1 |
| Kabiersch, A | 1 |
| Newcombe, J | 1 |
| Albrecht, D | 1 |
| Nagel, R | 1 |
| Kölln, CP | 1 |
| Roussan, MS | 1 |
| Gordon, S | 1 |
| Beck, CW | 1 |
| Bender, MJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of Multiple Sclerosis Using Over the Counter Inosine[NCT00067327] | Phase 2 | 30 participants | Interventional | 2002-02-28 | Completed | ||
| Randomized, Comparative, Double Blind Controlled Phase II Clinical Trial, to Evaluate the Efficacy of ApE in Patients With Multiple Sclerosis (MS).[NCT02280876] | Phase 1/Phase 2 | 30 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for uric acid and Multiple Sclerosis
| Article | Year |
|---|---|
Inosine in Neurodegenerative Diseases: From the Bench to the Bedside.
Topics: Alzheimer Disease; Amyotrophic Lateral Sclerosis; Antioxidants; Humans; Inosine; Multiple Sclerosis; | 2022 |
Mendelian randomization study shows no causal effects of serum urate levels on the risk of MS.
Topics: Genome-Wide Association Study; Humans; Mendelian Randomization Analysis; Multiple Sclerosis; Uric Ac | 2021 |
Low serum uric acid levels in patients with multiple sclerosis and neuromyelitis optica: An updated meta-analysis.
Topics: Biomarkers; Humans; Multiple Sclerosis; Neuromyelitis Optica; Uric Acid | 2016 |
The review of most frequently occurring medical disorders related to aetiology of autism and the methods of treatment.
Topics: Ammonia; Autistic Disorder; Child; Chronic Disease; Delivery of Health Care, Integrated; Gastrointes | 2010 |
Serum uric acid levels in patients with multiple sclerosis: a meta-analysis.
Topics: Humans; Multiple Sclerosis; Uric Acid | 2012 |
Bio-markers of disease activity and response to therapy in multiple sclerosis.
Topics: Antibodies, Anti-Idiotypic; Antigens, Surface; Apoptosis; Autoantigens; Biomarkers; Down-Regulation; | 2004 |
[Uric acid and multiple sclerosis].
Topics: Biomarkers; Free Radical Scavengers; Humans; Inosine; Multiple Sclerosis; Reference Values; Uric Aci | 2004 |
Uric acid in multiple sclerosis.
Topics: Animals; Antioxidants; Biomarkers; Humans; Multiple Sclerosis; Uric Acid | 2006 |
Role of uric acid in multiple sclerosis.
Topics: Blood-Brain Barrier; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Female; | 2008 |
Immunological indicators of disease activity and prognosis in multiple sclerosis.
Topics: Antigens, Surface; Biomarkers; Cytokines; Humans; Immune System; Matrix Metalloproteinases; Multiple | 2002 |
4 trials available for uric acid and Multiple Sclerosis
| Article | Year |
|---|---|
Modulation of serum uric acid levels by inosine in patients with multiple sclerosis does not affect blood pressure.
Topics: Administration, Oral; Adult; Blood Pressure; Cross-Over Studies; Double-Blind Method; Female; Humans | 2010 |
Low serum urate levels are associated to female gender in multiple sclerosis patients.
Topics: Adolescent; Adult; Aged; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Sex Characteristics; | 2012 |
Serum uric acid and multiple sclerosis.
Topics: Adolescent; Adult; Chronic Disease; Female; Gadolinium DTPA; Humans; Magnetic Resonance Imaging; Mal | 2002 |
Variation of serum uric acid levels in multiple sclerosis during relapses and immunomodulatory treatment.
Topics: Adolescent; Adult; Aged; Disability Evaluation; Female; Humans; Immunoenzyme Techniques; Immunologic | 2008 |
52 other studies available for uric acid and Multiple Sclerosis
| Article | Year |
|---|---|
The relationship between neutrophil/lymphocyte ratio and uric acid levels in multiple sclerosis patients.
Topics: Humans; Lymphocytes; Multiple Sclerosis; Neutrophils; Retrospective Studies; Uric Acid | 2021 |
Serum uric acid concentrations are directly associated with the presence of benign multiple sclerosis.
Topics: Adult; Biomarkers; Cross-Sectional Studies; Disability Evaluation; Female; Humans; Logistic Models; | 2017 |
BJ-2266 ameliorates experimental autoimmune encephalomyelitis through down-regulation of the JAK/STAT signaling pathway.
Topics: Aminopyridines; Animals; Benzamides; Cell Differentiation; Cells, Cultured; Encephalomyelitis, Autoi | 2017 |
Monosodium Urate Crystals Activate the Inflammasome in Primary Progressive Multiple Sclerosis.
Topics: Adult; Aged; Apoptosis; Caspase 1; Caspase 8; Female; Humans; Inflammasomes; Inflammation; Interleuk | 2018 |
Disability in multiple sclerosis is associated with age and inflammatory, metabolic and oxidative/nitrosative stress biomarkers: results of multivariate and machine learning procedures.
Topics: Adult; Age Factors; Biomarkers; Body Mass Index; Cholesterol, HDL; Disability Evaluation; Female; Ho | 2019 |
A logically derived diet to stop MS relapses.
Topics: Demography; Endocrine System; Environment; Humans; Hypothalamo-Hypophyseal System; Kidney; Multiple | 2013 |
Long-term effects of whole body cryostimulation on uric acid concentration in plasma of secondary progressive multiple sclerosis patients.
Topics: Adult; Biomarkers; Cryotherapy; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Multiple Scle | 2013 |
Uric acid: a potential biomarker of multiple sclerosis and of its disability.
Topics: Adolescent; Adult; Aged; Biomarkers; Disabled Persons; Female; Humans; Male; Middle Aged; Multiple S | 2015 |
Clinical associations between gout and multiple sclerosis, Parkinson's disease and motor neuron disease: record-linkage studies.
Topics: Adult; Aged; Databases, Factual; England; Female; Gout; Hospitalization; Humans; Male; Middle Aged; | 2015 |
Serum uric acid levels in patients with infections of central nervous system.
Topics: Adult; Aged; Antioxidants; Central Nervous System; Female; Humans; Infections; Male; Meningitis; Mid | 2016 |
Angiogenic factors are associated with multiple sclerosis.
Topics: Adult; Angiogenesis Inducing Agents; Angiopoietin-1; Antibodies; Disability Evaluation; Endoglin; En | 2016 |
Elevated cerebrospinal fluid uric acid during relapse of neuromyelitis optica spectrum disorders.
Topics: Adolescent; Adult; Aged; Blood-Brain Barrier; Humans; Middle Aged; Multiple Sclerosis; Neuromyelitis | 2017 |
Insulin resistance, atherogenicity, and iron metabolism in multiple sclerosis with and without depression: Associations with inflammatory and oxidative stress biomarkers and uric acid.
Topics: Adult; Atherosclerosis; Biomarkers; C-Reactive Protein; Case-Control Studies; Depressive Disorder; F | 2017 |
Increase of uric acid and purine compounds in biological fluids of multiple sclerosis patients.
Topics: Case-Control Studies; Health; Humans; Multiple Sclerosis; Purines; Uric Acid | 2009 |
Serum uric acid and risk of multiple sclerosis.
Topics: Age Factors; Age of Onset; Analysis of Variance; Case-Control Studies; Cohort Studies; Female; Human | 2009 |
Cerebrospinal fluid and serum uric acid levels in patients with multiple sclerosis.
Topics: Adult; Brain; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Ner | 2009 |
The treatment of multiple sclerosis with inosine.
Topics: Humans; Inosine; Multiple Sclerosis; Uric Acid | 2009 |
Serum uric acid levels and neuromyelitis optica.
Topics: Adolescent; Adult; Aged; Brain Infarction; Case-Control Studies; Child; Child, Preschool; China; Coh | 2010 |
Blood lipids, homocysteine, stress factors, and vitamins in clinically stable multiple sclerosis patients.
Topics: Adolescent; Adult; Antioxidants; Case-Control Studies; Female; Folic Acid; Homocysteine; Humans; Lip | 2010 |
Serum uric acid levels in multiple sclerosis patients inversely correlate with disability.
Topics: Adolescent; Adult; Aged; Biomarkers; Disability Evaluation; Female; Humans; Male; Middle Aged; Multi | 2011 |
Serum total antioxidant capacity in patients with multiple sclerosis.
Topics: Adult; alpha-Tocopherol; Antioxidants; Ascorbic Acid; Bilirubin; Case-Control Studies; Cross-Section | 2011 |
Endocrine and phototransduction effects in the prevention of multiple sclerosis.
Topics: Age Factors; Blood-Brain Barrier; Demography; Endocrine System; Humans; Incidence; Multiple Sclerosi | 2011 |
Antioxidant status of bilirubin and uric acid in patients with myasthenia gravis.
Topics: Adolescent; Adult; Bilirubin; Child; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Myasthen | 2012 |
Reduced serum uric acid levels in neuromyelitis optica: serum uric acid levels are reduced during relapses in NMO.
Topics: Adult; Female; Humans; Immunologic Factors; Interferon-beta; Magnetic Resonance Imaging; Male; Middl | 2012 |
Correlations between serum uric acid level and disease activity, intrathecal inflammation reactivity in patients with multiple sclerosis.
Topics: Adolescent; Adult; Aged; Case-Control Studies; Disease Progression; Female; Humans; Inflammation; In | 2012 |
High-dose methylprednisolone therapy in multiple sclerosis increases serum uric acid levels.
Topics: Adult; Case-Control Studies; Female; Humans; Male; Methylprednisolone; Multiple Sclerosis; Reagent K | 2002 |
Therapeutic intervention in experimental allergic encephalomyelitis by administration of uric acid precursors.
Topics: Administration, Oral; Animals; Biotransformation; Chromatography, High Pressure Liquid; Drug Evaluat | 2002 |
Uric acid: a novel treatment strategy for multiple sclerosis.
Topics: Antioxidants; Humans; Multiple Sclerosis; Reactive Nitrogen Species; Uric Acid | 2003 |
Serum uric acid levels in optic neuritis.
Topics: Adult; Antioxidants; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Scleros | 2004 |
Altered circadian relationship between serum nitric oxide, carbon dioxide, and uric acid in multiple sclerosis.
Topics: Adult; Aged; Carbon Dioxide; Case-Control Studies; Circadian Rhythm; Female; Humans; Male; Middle Ag | 2004 |
Urate oxidation in CSF and blood of patients with inflammatory disorders of the nervous system.
Topics: Allantoin; Blood-Brain Barrier; Brain; Central Nervous System Diseases; Guillain-Barre Syndrome; Hum | 2004 |
No evidence of increased oxidative degradation of urate to allantoin in the CSF and serum of patients with multiple sclerosis.
Topics: Adult; Allantoin; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Oxidative Stress; Uric Acid | 2005 |
Serum uric acid levels and leukocyte nitric oxide production in multiple sclerosis patients outside relapses.
Topics: Adult; Case-Control Studies; Female; Humans; Interferon-beta; Leukocytes; Male; Middle Aged; Multipl | 2005 |
Serum uric acid, dehydroepiandrosterone sulphate, and apolipoprotein E genotype in benign vs. progressive multiple sclerosis.
Topics: Adult; Apolipoproteins E; Dehydroepiandrosterone; Disease Progression; Female; Genotype; Humans; Mal | 2005 |
Serum uric acid and multiple sclerosis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Case-Control Studies; Drug Administration Schedul | 2006 |
Serum uric acid levels of patients with multiple sclerosis and other neurological diseases.
Topics: Adolescent; Adult; Aged; Brain Diseases; Child; Child, Preschool; Encephalitis; Female; Humans; Male | 2008 |
Serum and cerebrospinal fluid uric acid levels in multiple sclerosis patients.
Topics: Blood-Brain Barrier; Humans; Multiple Sclerosis; Reference Values; Uric Acid | 2008 |
HPLC method for measurement of purine nucleotide degradation products in cerebrospinal fluid.
Topics: Adult; Brain Ischemia; Chromatography, High Pressure Liquid; Humans; Hydrogen-Ion Concentration; Hyp | 1996 |
Prevention of experimental allergic encephalomyelitis by targeting nitric oxide and peroxynitrite: implications for the treatment of multiple sclerosis.
Topics: Animals; Brain; Bridged-Ring Compounds; Cyclic N-Oxides; Encephalomyelitis, Autoimmune, Experimental | 1997 |
Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis.
Topics: Animals; Encephalomyelitis, Autoimmune, Experimental; Female; Humans; Mice; Mice, Knockout; Multiple | 1998 |
Cerebrospinal fluid hypoxanthine, xanthine and uric acid levels may reflect glutamate-mediated excitotoxicity in different neurological diseases.
Topics: Adult; Albumins; Central Nervous System Diseases; Cerebrovascular Disorders; Chromatography, High Pr | 1997 |
[Uric acid as a scavenger in oxidative stress].
Topics: Animals; Antioxidants; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Free Rad | 1999 |
Uric acid, a peroxynitrite scavenger, inhibits CNS inflammation, blood-CNS barrier permeability changes, and tissue damage in a mouse model of multiple sclerosis.
Topics: Animals; Apoptosis; Blood-Brain Barrier; Disease Models, Animal; Encephalomyelitis, Autoimmune, Expe | 2000 |
Circadian relationship of serum uric acid and nitric oxide.
Topics: Adult; Circadian Rhythm; Humans; Male; Middle Aged; Multiple Sclerosis; Nitric Oxide; Uric Acid | 2000 |
Protection of myelin basic protein immunized mice from free-radical mediated inflammatory cell invasion of the central nervous system by the natural peroxynitrite scavenger uric acid.
Topics: Animals; Blood-Brain Barrier; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; F | 2000 |
Prospects for the treatment of multiple sclerosis by raising serum levels of uric acid, a scavenger of peroxynitrite.
Topics: Humans; Multiple Sclerosis; Nitrates; Oxidants; Time Factors; Uric Acid | 2001 |
Uric acid levels in sera from patients with multiple sclerosis.
Topics: Adolescent; Adult; Aged; Brain; Disability Evaluation; Female; Humans; Male; Middle Aged; Multiple S | 2001 |
Uric acid levels in patients with multiple sclerosis: analysis in mono- and dizygotic twins.
Topics: Female; Humans; Male; Multiple Sclerosis; Twins, Dizygotic; Twins, Monozygotic; Uric Acid | 2001 |
Measurement of low-molecular-weight antioxidants, uric acid, tyrosine and tryptophan in plaques and white matter from patients with multiple sclerosis.
Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Brain Chemistry; Chromatography, High Pressure Liquid; | 1992 |
Electrohydraulic waves (Urat I) for the treatment of vesical calculi.
Topics: Aged; Anesthesia, Endotracheal; Anesthesia, Local; Anesthesia, Spinal; Biguanides; Calcium; Drug Com | 1972 |
Effect of a new antispasticity drug on neurogenic bladder function: preliminary report.
Topics: Adult; Aminobutyrates; Benzene Derivatives; Female; Humans; Male; Middle Aged; Multiple Sclerosis; M | 1973 |
Aragonite, CaCO3, as urinary calculi.
Topics: Adenine Nucleotides; Adult; Calcium; Calcium Carbonate; Crystallography; Female; Gluconates; Humans; | 1969 |